Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options and restricted stock units (RSUs) to three new employees as inducement awards effective May 12, 2021. The stock options total 48,750 shares with an exercise price of $1.22, vesting over three years. The RSUs granted to one employee total 2,375 shares, also vesting over three years. These awards aim to incentivize new hires as part of the Company’s growth strategy, reflecting a commitment to attract talent in the pharmaceuticals sector.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that its Annual Meeting of Stockholders, originally held on May 13, 2021, was adjourned due to a lack of quorum, with a reconvene scheduled for June 11, 2021, at 8:30 AM PST. Over 80% of votes cast favored Proposals 2, 3, 4, and 6. Proposal 3 aims to increase the authorized shares of Common Stock from 150 million to 290 million, providing flexibility for future business opportunities. Stockholders are encouraged to participate in the voting process as approximately 11% of eligible shares are still needed to reach quorum.
Jaguar Health (NASDAQ:JAGX) announced a webcast to discuss Q1 2021 financial results and business updates on May 17, 2021, at 8:30 AM ET. Interested participants can register using the provided link. Jaguar is focused on developing plant-based medicines for gastrointestinal issues, particularly chronic diarrhea. Its product, Mytesi (crofelemer), is FDA-approved for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable practices in harvesting its active ingredients.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a registered direct offering of 7,647,000 shares, raising approximately $10.8 million. The offering price is set at $1.41 per share, with proceeds aimed at supporting its subsidiary Napo EU S.p.A. This includes potential capital expenditures, licenses, acquisitions, and growth opportunities. The company also terminated its at-the-market financing program effective April 26, 2021. Closing is expected around May 3, 2021, pending customary conditions satisfaction.
Jaguar Health (NASDAQ:JAGX) announced that an abstract on patient outcomes related to cancer therapy-related diarrhea was accepted for a poster presentation at the 2021 ASCO Annual Meeting, occurring virtually from June 4-8, 2021. The study, titled The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence, highlights the significance of diarrhea in cancer treatment. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting a pivotal Phase 3 clinical trial of crofelemer (Mytesi), aimed at preventing diarrhea in cancer patients.
Jaguar Health, Inc. (JAGX) has announced a webcast interview featuring CEO Lisa Conte and Dragon SPAC lead sponsor Josh Mailman on April 23, 2021, at 8:30 AM Eastern. The discussion will cover the business overview of Napo EU S.p.A., its wholly owned Italian subsidiary. The Company is seeking conditional marketing authorization from the European Medicines Agency for crofelemer to treat COVID-related diarrhea. Jaguar is focused on developing sustainable, plant-based pharmaceuticals for gastrointestinal distress.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast interview on April 23, 2021, at 8:30 AM Eastern, featuring CEO Lisa Conte, aimed at providing an overview of Napo EU S.p.A., its Italian subsidiary. The company has also launched a rebranded Napo EU website, showcasing a new logo and promising expanded content. Mytesi®, Jaguar's key product, is the only FDA-approved plant-based medication for noninfectious diarrhea in adults with HIV/AIDS. The company focuses on developing sustainable plant-based pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announced an upsizing of its at-the-market (ATM) financing program by $15.3 million on April 15, 2021. This increase aims to provide future funding, with the company stating it does not plan to issue shares immediately. The company is pursuing conditional marketing authorization for crofelemer for COVID-related diarrhea. Additionally, Jaguar is merging Napo EU with the Dragon SPAC, anticipated for mid-2021, which is expected to support clinical efforts related to diarrhea in cancer patients. An educational contest is also launching for HIV awareness.
Jaguar Health (NASDAQ:JAGX) announces the acceptance of an abstract related to cancer therapy-related diarrhea (CTD) for poster presentation at the 2021 ASCO Annual Meeting, scheduled for June 4-8, 2021. This abstract is from Napo Pharmaceuticals, a subsidiary of Jaguar. In total, three CTD-related abstracts have been accepted for the event. The ASCO meeting received over 5,400 submissions this year. The press release highlights the significance of addressing CTD, a common side effect of cancer therapies that can impact treatment adherence and patient outcomes.
Jaguar Health (NASDAQ:JAGX) announced an amendment to its equity purchase agreement with Oasis Capital, increasing the stock purchase price from $0.436 to $3.00 per share. This amendment allows Oasis to purchase up to $2.0 million of Jaguar common stock over a 36-month period. The new price reflects the stock's recent performance, providing Jaguar access to capital for working needs while focusing on becoming a cash flow positive business through its product, Mytesi. The company will also issue a warrant for 100,000 common shares to Oasis as part of this agreement.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
